What is the recommended evaluation and management algorithm for a pregnant patient with severe pulmonary arterial hypertension (WHO functional class III–IV)?

Evaluation and Management Algorithm for Severe PAH in Pregnancy

If pregnancy occurs in a patient with severe PAH (WHO FC III-IV), immediate referral to a specialized pulmonary hypertension center with multidisciplinary care is mandatory, and termination should be offered given the 12-30% maternal mortality risk even with optimal management. 1

Initial Assessment and Counseling

When pregnancy is discovered in a patient with severe PAH:

• Offer pregnancy termination immediately - This remains the guideline-recommended approach given substantial mortality risk (historically 30-50%, more recently 12% with optimal care) 1
• Termination should be performed at a tertiary center experienced in PAH management due to anesthesia risks 2
• If the patient chooses to continue pregnancy despite counseling, proceed with the algorithm below

Risk Stratification

Evaluate the following high-risk features:

• WHO functional class III-IV status (already present in this scenario)
• Hemodynamic severity: Mean PAP >50 mmHg, elevated PVR
• Right ventricular function: Evidence of RV failure on echocardiography
• NT-proBNP levels: Elevated levels indicate worse prognosis
• Oxygen saturation: SpO2 <90% significantly increases risk 3

Critical timing considerations: Maternal death typically occurs in the last trimester or first months postpartum due to pulmonary hypertensive crises, thrombosis, or refractory right heart failure 2

Management Protocol for Continued Pregnancy

Immediate Actions

1. Transfer to specialized PH center with expertise in PAH, high-risk obstetrics, and cardiovascular anesthesiology 1

2. Early hospitalization once fetus is viable for continuous monitoring 1

3. Multidisciplinary team assembly:

   • Pulmonary hypertension specialists
   • Maternal-fetal medicine
   • Cardiovascular anesthesiology
   • Neonatology 1

Medical Management

PAH-Specific Therapy:

• Continue existing PAH medications if already on therapy, with important caveats 2
• Avoid Category X medications: Bosentan, ambrisentan, macitentan, and riociguat are contraindicated (teratogenic) 1
• Safe options include:
  • IV epoprostenol (most experience in pregnancy)
  • Inhaled nitric oxide
  • Oral calcium channel blockers (in vasoreactive patients)
  • Sildenafil (limited data but used) 1
• Consider IV prostacyclin or aerosolized iloprost for hemodynamic support peripartum 2

Supportive Care:

• Supplemental oxygen: Maintain SpO2 >91% at all times 1
• Cautious fluid management: Avoid volume overload while preventing hypotension 1
• Diuretics: As needed for volume management 1
• Dobutamine: For inotropic support if needed 1

Anticoagulation:

• Continue if already indicated outside pregnancy 2
• Use subcutaneous LMWH or UFH (preferred over oral anticoagulants during pregnancy due to bleeding risk) 2
• Monitor anti-Xa levels (LMWH) or aPTT (UFH) carefully
• Be aware of drug interactions with PAH therapies 2

Hemodynamic Monitoring

Pulmonary artery catheter use is controversial:

• May be helpful for close hemodynamic monitoring and therapy titration 1
• However, carries risk of pulmonary artery rupture in PAH patients 2
• Recommendation: Reserve for patients with severe hemodynamic instability; rely primarily on non-invasive monitoring (echocardiography, clinical assessment) 2

Delivery Planning

Timing

• Plan elective delivery between 32-37 weeks (balance fetal maturity against maternal decompensation risk) 4
• Avoid waiting for spontaneous labor due to unpredictable hemodynamic stress

Mode of Delivery

The optimal delivery mode remains controversial 1:

• Vaginal delivery: Successfully reported in case series; avoids surgical stress 1
• Cesarean section: Also successfully reported; allows controlled timing 1
• Current practice: Most centers favor cesarean section (5 of 7 deliveries in recent series) with planned approach 4

Critical delivery principles:

• Avoid general anesthesia (high mortality risk) 2
• Use epidural/regional anesthesia whenever possible 5
• Maintain circulating volume
• Prevent systemic hypotension, hypoxia, and acidosis (all precipitate RV failure) 2
• Have vasopressors immediately available for vasovagal events

Postpartum Management

The highest risk period is immediately postpartum (dramatic volume shifts from vena cava decompression and uterine blood return) 1, 6:

• Monitor in PH intermediate care/ICU for minimum 72 hours, ideally 5-7 days 4
• Continue aggressive hemodynamic monitoring
• Maintain PAH-specific therapies
• Continue oxygen supplementation
• Watch for signs of RV failure, arrhythmias, thromboembolism
• Risk extends through 6 weeks postpartum when hemodynamic changes fully regress 1, 6

Common Pitfalls to Avoid

1. Underestimating postpartum risk: Most deaths occur postpartum, not during pregnancy itself
2. Using estrogen-containing contraceptives: Increase VTE risk; use dual mechanical barrier methods or progesterone-only preparations 1
3. Discontinuing anticoagulation: Maintain throughout pregnancy if indicated
4. General anesthesia: Associated with significantly higher mortality 2
5. Late presentation to specialized center: Early transfer is critical for optimal outcomes

Fetal Considerations

Expect increased risk of:

• Small-for-gestational-age infants
• Preterm birth
• Congenital anomalies
• Neonatal asphyxia 1, 3
• Neonatal survival rates: 87-89% 2

Contraception Counseling for Future

• Avoid estrogen-containing contraceptives (VTE risk) 1
• Bosentan reduces hormonal contraception efficacy 1
• Recommend dual mechanical barrier methods or progesterone-only preparations (medroxyprogesterone, etonogestrel, levonorgestrel IUD) 5
• Counsel that PAH may permanently worsen after pregnancy even if delivery is successful 1